Hodge JW - Search Results

1

Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.

Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H. Slavin-Chiorini DC, et al. Among authors: hodge jw. Cancer Gene Ther. 2004 Oct;11(10):665-80. doi: 10.1038/sj.cgt.7700741. Cancer Gene Ther. 2004. PMID: 15354200

2

Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.

Hodge JW, Abrams S, Schlom J, Kantor JA. Hodge JW, et al. Cancer Res. 1994 Nov 1;54(21):5552-5. Cancer Res. 1994. PMID: 7522961

3

Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.

Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Hodge JW, et al. Cancer Res. 1995 Aug 15;55(16):3598-603. Cancer Res. 1995. PMID: 7543017

4

A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate.

Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA. Hodge JW, et al. Int J Cancer. 1995 Oct 9;63(2):231-7. doi: 10.1002/ijc.2910630215. Int J Cancer. 1995. PMID: 7591210

5

Carcinoembryonic antigen as a target for cancer vaccines.

Hodge JW. Hodge JW. Cancer Immunol Immunother. 1996 Nov;43(3):127-34. doi: 10.1007/s002620050313. Cancer Immunol Immunother. 1996. PMID: 9001565 Review.

6

Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.

Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J. Abrams SI, et al. Among authors: hodge jw. J Immunother. 1997 Jan;20(1):48-59. doi: 10.1097/00002371-199701000-00005. J Immunother. 1997. PMID: 9101413

7

Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses.

Uzendoski K, Kantor JA, Abrams SI, Schlom J, Hodge JW. Uzendoski K, et al. Among authors: hodge jw. Hum Gene Ther. 1997 May 1;8(7):851-60. doi: 10.1089/hum.1997.8.7-851. Hum Gene Ther. 1997. PMID: 9143911

8

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.

Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Hodge JW, et al. Vaccine. 1997 Apr-May;15(6-7):759-68. doi: 10.1016/s0264-410x(96)00238-1. Vaccine. 1997. PMID: 9178479

9

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.

Kalus RM, Kantor JA, Gritz L, Gómez Yafal A, Mazzara GP, Schlom J, Hodge JW. Kalus RM, et al. Among authors: hodge jw. Vaccine. 1999 Feb 26;17(7-8):893-903. doi: 10.1016/s0264-410x(98)00275-8. Vaccine. 1999. PMID: 10067696

10

Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus.

Lorenz MG, Kantor JA, Schlom J, Hodge JW. Lorenz MG, et al. Among authors: hodge jw. Hum Gene Ther. 1999 Mar 1;10(4):623-31. doi: 10.1089/10430349950018698. Hum Gene Ther. 1999. PMID: 10094205

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results